Ling Wan Li

US Patent:

7858539, Dec 28, 2010

Filed:

Apr 9, 2007

Appl. No.:

11/784711

Inventors:

Ling Li - Blue Bell PA, US
Shulong Li - Spartanburg SC, US
Jeffrey S. Lane - Moore SC, US

Assignee:

Milliken & Company - Spartanburg SC

International Classification:

B32B 27/04

US Classification:

442123, 811559

Abstract:

Provided herein are processes for topically applying an antimicrobial finish to a textile substrate, such as a yarn, a fabric, a composite, or an assembled article (for example, a garment). Specifically, the antimicrobial finish is based on hindered amine compounds that are applied in an aqueous bath (such as a commercial or home laundry setting), using the factors of pH and compound solubility to promote the formation of a durable antimicrobial halamine finish. Advantageously, the antimicrobial finish, which may be applied to fabrics made of any of a variety of fiber types and combinations of fiber types, has been found to be durable to repeated launderings.

US Patent:

7263132, Aug 28, 2007

Filed:

Oct 31, 2002

Appl. No.:

10/285269

Inventors:

Jyhchau Horng - Warren NJ, US
Ling Li - New Providence NJ, US

Assignee:

Mitsubishi Electric Research Laboratories, Inc. - Cambridge MA

International Classification:

H04B 7/02

US Classification:

375267, 375299, 375347

Abstract:

A method for transmitting a stream of data symbols in a multiple-input/multiple-output (MIMO) wireless communications system including Ntransmitting antennas. The stream of data symbols is first demultiplexed into M sub-streams, where M=N/2. Then, space-time transmit diversity encoding is applied to each sub-stream to generate a pair of transmit signals. Power is allocated dynamically to each transmit signal of each pair of transmit signals according to a corresponding feedback signal received from a receiver of the transmit signal. The feedback signal including a ratio of magnitude sums of channel coefficients for channels used for the transmit signals.

US Patent:

20090093560, Apr 9, 2009

Filed:

Sep 17, 2008

Appl. No.:

12/283934

Inventors:

Paul Van Rheenen - Warminster PA, US
Eric G. Lundquist - North Wales PA, US
Brian H. Clare - Portland OR, US
Ling Li - Blue Bell PA, US

International Classification:

C08J 9/00
C08L 27/14
C08L 33/10
C08L 33/26

US Classification:

521134, 525199, 525227, 525218

Abstract:

A halogenated polymer containing a functionalized polymer and optionally a blowing agent.

US Patent:

20120322936, Dec 20, 2012

Filed:

Jun 18, 2012

Appl. No.:

13/525918

Inventors:

Ling Li - Blue Bell PA, US
Barrett Bobsein - Sellersville PA, US

International Classification:

C08G 18/83
C09D 175/08

US Classification:

524500, 525460

Abstract:

The present invention relates to a hydrophobically modified alkylene oxide urethane polymer comprising structural units of a polyalkylene glycol, an alkoxylated polyol having 50 to 250 repeating alkylene oxide units, an aliphatic diisocyanate, and a capping agent, and a process for preparing the polymer. The composition of the present invention is useful as a rheology modifier for coating compositions.

US Patent:

20220281844, Sep 8, 2022

Filed:

Aug 5, 2020

Appl. No.:

17/632811

Inventors:

- Princeton NJ, US
Kandhasamy Sarkunam - Hosur, IN
Ling Li - Pennington NJ, US
Lidet A. Negash - Plainsboro NJ, US
John Hynes - Washington Crossing PA, US

International Classification:

C07D 401/14
C07D 401/04
C07D 215/54
C07D 417/04
C07D 405/14
C07D 413/14
C07D 417/14
C07D 409/14
C07D 471/04
C07D 213/22
C07D 213/04
C07D 277/22
C07D 213/38

Abstract:

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CRor N; Y is CRor N; Z is CRor N; provided that zero or 1 of X, Y, and Z is N; and R, R, R, R, R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

US Patent:

20220267348, Aug 25, 2022

Filed:

Jul 22, 2020

Appl. No.:

17/628976

Inventors:

- Princeton NJ, US
Ling Li - Pennington NJ, US
Hong Wu - New Hope PA, US
John Hynes - Washington Crossing PA, US

International Classification:

C07D 495/04
C07D 513/04

Abstract:

Disclosed are compounds of Formula (I) [INSERT CHEMICAL STRUCTURE HERE] (I) or a salt or prodrug thereof, wherein: X is CR4 or N; and R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

US Patent:

20210147357, May 20, 2021

Filed:

Aug 8, 2018

Appl. No.:

16/636670

Inventors:

- Princeton NJ, US
Ling Li - Pennington NJ, US
John L. Gilmore - Yardley PA, US

International Classification:

C07D 207/16

Abstract:

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is —CH— or —C(O)—; Ris —OH or —OP(O)(OH); L is a bond, —CH—, or —C(O)—; Ris n-Calkyl; each Ris independently selected from Cl and —CH; and n is zero, 1, or 2; provided that if X is —CH—, then L is —CH— or —C(O)—. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor SlP, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

US Patent:

20210147361, May 20, 2021

Filed:

Aug 8, 2018

Appl. No.:

16/636662

Inventors:

- Princeton NJ, US
Ling Li - Pennington NJ, US

International Classification:

C07D 213/53
C07D 207/12
C07D 211/40
C07D 211/96
A61P 37/06

Abstract:

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; Ris —OH or —OP(O)(OH); Lis —CR═N—O—CRR— or CRR—O—N═CR; Lis a bond, —C(O)—, or S(O)—; and R, R, R, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.